GlyCardial Diagnostics completes recruitment in the EDICA trial

GlyCardial Diagnostics completes recruitment in the EDICA trial

GlyCardial Diagnostics today announces the completion of the enrolment in the EDICA trial. The study has been conducted in 10 sites in Spain and UK (Lister Hospital – East and North Hertfordshire NHS Trust, Hospital Universitario La Paz, Hospital de la Santa Creu i Sant Pau, Hospital Universitario Central de Asturias, Hospital Clínico Universitario Santiago, Hospital Álvaro Cunqueiro, Hospital Universitario San Juan, West Middlesex University Hospital, Hospital General Universitario Gregorio Marañón, and Hospital Universitario Virgen Macarena).

This is a key milestone for the company that has been possible due to the commitment and hard work of all the sites, and even more in the context of the COVID-19 pandemic.

The EDICA trial it is designed to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of myocardial ischaemia, and is part of the AGLYC Project, funded by the European Commission under the Horizon 2020 Framework Programme SME Instrument.